Document is current
Any future updates will be listed below
-
Authors
Phoka, Andri
van den Bemt, Bart J. F. https://orcid.org/0000-0002-8560-9514
Lubrano, Ennio https://orcid.org/0000-0001-6189-5328
Singh, Inderjit
Fernández-Carballido, Cristina https://orcid.org/0000-0002-0910-4944
Parow, Detlev
Webb, Dale
Lacombe, Fabienne
Harrington, Laura
Baraliakos, Xenofon https://orcid.org/0000-0002-9475-9362
-
Funding
Funding for this research was provided by:
UCB Pharma
- License Information
-
More Information
Article History
Received: 15 December 2023
Accepted: 11 March 2024
First Online: 25 April 2024
Declarations
:
: Stakeholder leads (namely, Andri Phoka, Bart J.F. van den Bemt and Xenofon Baraliakos) received an honorarium for their participation in the initial workshop and they and the other axSpA CC members (Ennio Lubrano, Inderjit Singh, Cristina Fernández-Carballido, Detlev Parow, Dale Webb, Fabienne Lacombe) received an honorarium from UCB for their time to complete the Delphi e-consultations and to attend the axSpA CC meeting or provide their input offline. UCB Pharma reviewed the manuscript to ensure scientific and medical clarity and accuracy only. Bart J.F. van den Bemt received honorarium for lectures/presentations from Lilly and support for attending meetings from AbbVie, Lilly and UCB. Cristina Fernández-Carballido received honoraria for lectures/presentations from AbbVie, Galapagos, Lilly, Novartis, Pfizer and UCB; consulting fees from AbbVie, Lilly, Novartis and UCB and support for attending meetings from AbbVie, Galapagos, Janssen, Lilly, Novartis, Roche and UCB. Detlev Parow received honoraria for advisory boards from Boehringer-Ingelheim, Hexal and UCB. Ennio Lubrano received honoraria for advisory boards and conference fees from AbbVie, Lilly, Novartis and UCB. Laura Harrington is an employee of Ogilvy Health. Xenefon Baraliakos received consultancy, research funding and honoraria from AbbVie, Amgen, Celltrion, Chugai, Lilly, Galapagos, Janssen, MSD, Novartis, Pfizer, Roche, Sandoz and UCB. National Axial Spondyloarthritis Society (on behalf of Dale Webb) received grant funding from AbbVie, Biogen, Lilly, Janssen, Novartis and UCB. Andri Phoka, Inderjit Singh and Fabienne Lacombe have nothing to disclose.
: There was no need to collect any type of patient data. Hence, the approval of an ethics committee was not required. Consent was obtained from all axSpA CC members as they were contracted by UCB Pharma to take part in this programme.
